| 0 (0%) | 09-27 00:49 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 64.46  |
1-year : | 72.41 |
| Resists | First : | 55.19 |
Second : | 62 |
| Pivot price | 51.75 |
|||
| Supports | First : | 44.17 |
Second : | 36.75 |
| MAs | MA(5) : | 46.61 |
MA(20) : | 53.43 |
| MA(100) : | 49.82 |
MA(250) : | 35.94 |
|
| MACD | MACD : | -3.2 |
Signal : | -2 |
| %K %D | K(14,3) : | 2.9 |
D(3) : | 3.5 |
| RSI | RSI(14): 20.4 |
|||
| 52-week | High : | 62.31 | Low : | 14.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELVN ] has closed above bottom band by 13.4%. Bollinger Bands are 109.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 46.07 - 46.51 | 46.51 - 46.78 |
| Low: | 43.24 - 43.82 | 43.82 - 44.16 |
| Close: | 44.09 - 45.03 | 45.03 - 45.59 |
Thu, 24 Sep 2026
ELVN Dec 2027 65.000 put (ELVN271217P00065000) stock price, news, quote and history - Yahoo Finance UK
Mon, 21 Sep 2026
Enliven Therapeutics Insider Sold Shares Worth $303,003, According to a Recent SEC Filing - finance.yahoo.com
Mon, 21 Sep 2026
Enliven Therapeutics (ELVN) CFO exercises options, sells 6,018 shares - Stock Titan
Thu, 17 Sep 2026
Fadi Haddad: ENABLE-1 Brings New ELVN-001 Data to CML - Oncodaily
Thu, 17 Sep 2026
Enliven Therapeutics (ELVN) officer lines up new stock sale - Stock Titan
Wed, 16 Sep 2026
ELVN: ELVN-001 targets a $16B global CML market with best-in-class efficacy and strong clinical momentum - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 73 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 6.2 (%) |
| Held by Institutions | 113.7 (%) |
| Shares Short | 8,260 (K) |
| Shares Short P.Month | 8,650 (K) |
| EPS | -1.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.22 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11 % |
| Return on Equity (ttm) | -15.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -67 (M) |
| Levered Free Cash Flow | -45 (M) |
| PE Ratio | -27.13 |
| PEG Ratio | 0 |
| Price to Book value | 3.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -48.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|